Lymphoma Clinical Trials & Research

Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:

Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.

Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.

Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.

Researchers are comparing mosunetuzumab to the usual treatment (rituximab) for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). They want to see if one drug is more effective than the other to shrink the cancer with a long-lasting response.

This clinical trial explores a novel approach to treating mantle cell lymphoma (MCL). Researchers are integrating targeted agents into standard induction and maintenance chemoimmunotherapy.  The people in this study have MCL that has not yet been treated.

Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.

BV-AVD is a combination of drugs used to treat advanced (stage 3 or 4) Hodgkin lymphoma. Researchers in this study want to see how well it works to treat early-stage bulky Hodgkin lymphoma. The people in this study have stage 1 or 2 bulky Hodgkin lymphoma that has not yet been treated.

Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.

Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.